Harvard Bioscience, Inc. (HBIO)

The share price experienced a significant decline of 65.69% between January 10, 2025, and January 8, 2026, but showed a positive return of 39.53% over the last six months. Harvard Bioscience reported Q2 2025 earnings per share (EPS) of -$0.01, exceeding analysts' expectations, with revenues of $20.5 million and a gross margin of 56.4%. Stephen DeNelsky was appointed to the Board. The company expanded its distribution agreement with Fisher Scientific to enhance customer reach in the United States. The announcement of the Q3 2025 earnings conference call preceded a significant positive market reaction, with the stock gaining 41.10% on that day. The company reported Q3 2025 revenues of $20.6 million, exceeding analyst expectations, and a gross margin of 58.4%, but the EPS of -$0.03 missed the forecasted $0.01. Harvard Bioscience completed debt refinancing with a growth financing package, extending debt maturity and enhancing financial flexibility. The company received a notice from Nasdaq regarding non-compliance with Listing Rule 5605(c)(2)(A) due to a director's resignation, requiring them to regain compliance by June 10, 2026.

The search results do not explicitly describe the demand seasonality for Harvard Bioscience, Inc.'s products and services. The company's products serve research scientists in various organizations, suggesting a relatively consistent demand driven by ongoing research and drug discovery efforts, but specific seasonal fluctuations in product demand are not detailed.

Harvard Bioscience, Inc. (HBIO) is a global developer, manufacturer, and marketer of technologies, products, and services for life science applications, operating within the Healthcare sector, specifically in the Medical Instruments & Supplies industry. The company focuses on scientific instruments for research and drug discovery, with a diverse product portfolio supporting research, pharmaceutical and therapy discovery, bioproduction, and preclinical testing for drug development. Major products include fluidics and laboratory equipment, molecular and cell analysis tools, and physiology and preclinical technologies. The company's brands include Biochrom, BTX, CMA, Data Sciences International (DSI), Harvard Apparatus, HEKA, Hugo Sachs Elektronik, KD Scientific, Multi Channel Systems (MCS), Panlab, and Warner Instruments.

Harvard Bioscience has a global presence with operations in North America, Europe, and China. The company markets its products directly in the US, the UK, Germany, France, Sweden, Canada, Italy, Spain, and China, and also utilizes a network of distributors in other countries. Its principal manufacturing facilities are located in New Brighton, Minnesota, Holliston, Massachusetts (USA), Reutlingen, Germany, Barcelona, Spain, and March, Germany.

Harvard Bioscience positions itself as a trusted partner in discovery, production, and safety and regulatory compliance, with over 120 years of innovating new technologies. The company emphasizes its global network of brands known for quality, cutting-edge technologies, and interoperable solutions. The Nasdaq non-compliance notice regarding its audit committee could be perceived as a governance weakness, potentially impacting investor confidence.

Harvard Bioscience, Inc. has significant institutional ownership, with 125 institutional owners holding a total of 18,412,135 shares, representing 37.29% to 37.37% of the company. Major institutional owners include AMH Equity Ltd, Harvey Partners, LLC, Vanguard Group Inc., Acadian Asset Management Llc, Meros Investment Management, LP, Renaissance Technologies Llc, BlackRock, Inc., and Granahan Investment Management Inc/ma. Specific major individual owners are not explicitly detailed.